Sandoz joins Accord in targeting US university

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Sandoz joins Accord in targeting US university

Viersen, Germany - May 9. 2020: Close up of mobile phone screen

The claim, filed this week against the University of California’s governing board, follows action by Accord Healthcare in October

Sandoz has become the second pharmaceutical company in the last few months to take action against the governing board of the University of California, according to a case filed with the England and Wales High Court on Tuesday, January 24.

The generics arm of Swiss outfit Novartis has filed pleadings against The Regents of the University of California. Publicly available documents are expected to be released in early February.

Sandoz filed the case in the patents division of the England and Wales High Court, but no further details are available at this stage.

The case follows action taken by Accord Healthcare in October last year in which the pharma company sought to invalidate a European patent and supplementary protection certificate (SPC) owned by the Regents.

That dispute arose after Accord signalled its intention to produce a capsule form of enzalutamide, a treatment for prostate cancer, in 2024 following the expiry of market exclusivity.

In the Accord case, the Regents first claimed that launching a capsule before the expiry date of a patent (EP 1,893,196) and SPC (GB13/079) it owns would amount to infringement.

In a counterclaim, Accord sought an order that the patent, called ‘diarylhydantoin compound’, is invalid and that the SPC is also invalid and should not come into force.

That case is expected to go to trial in the coming months. It is not known at this stage if the Sandoz dispute surrounds the same claims.

Bristows is representing Sandoz, whereas the Regents’ counsel have not been announced yet. In the Accord case, Pinsent Masons is acting for Accord while the Regents is being represented by Kirkland & Ellis.

more from across site and SHARED ros bottom lb

More from across our site

The firm explains how it secured a $170.6 million verdict against the government in a patent dispute surrounding airport technology, and why the case led to interest from other inventors
Developments of note included the court partially allowing a claim concerning confidentiality clubs and a decision involving technology used in football matches
The firm said adding capability in the French capital completes its coverage of all major patent litigation jurisdictions as it strives for UPC excellence
Marc Fenster explains how keeping the jury focused on the most relevant facts helped secure a $279m win for his client against Samsung
Clients are divided on what externally funded IP firms bring to the table, so those firms must prove why the benefits outweigh the downsides
Rahul Bhartiya, AI coordinator at the EUIPO, discusses the office’s strategy, collaboration with other IP offices, and getting rid of routine tasks
A boom in transactional work and a heightened awareness of IP have helped boost revenue for the rebranded commercial services team
Clemens Heusch, head of global litigation and dispute resolution at Nokia, tells us why open conversations – and respectful challenges – lead to the best results
Siegmund Gutman, who joined Mintz one year ago, explains the firm’s approach to life sciences litigation and what it means for hiring plans
The merger of two IP boutiques could prompt others to follow suit and challenge Australia’s externally funded firms
Gift this article